Colloquium on Innovation Policy
Professors Rochelle Dreyfuss and Katherine Strandburg
Schedule
Spring 2012
Topic: To examine innovation in the health care field, looking at such matters as the relationship between intellectual property, encouraging medical advances, and assuring appropriate public access to these advances; the special problem of developing countries; rights over personal patient data and the use of such data in research and marketing; the impact of personalized medicine on IP paradigms; controversial attempts to deal with the trade in counterfeit drugs; and competition issues related to innovation and intellectual property.
| Thursday, January 26 |
Heidi Williams, Assistant Professor, MIT Department of Economics |
| Thursday, February 9 |
Christopher Beauchamp, Assistant Professor of Law, Brooklyn Law School |
| Thursday, February 16 |
Walter Powell, Professor of Education; Professor of Sociology, Organizational Behavior, Management Science, Communication, and Public Policy, Stanford University, Department of Education |
| Thursday, February 23 |
Barbara Evans, Professor of Law, University of Houston Law Center |
| Thursday, March 1 |
Kara Swanson, Associate Professor of Law, Northeastern University School of Law |
| Thursday, March 22 |
Guy David, Assistant Professor of Health Care Management, The Wharton School, University of Pennsylvania |
| Thursday, March 29 |
Angelina Godoy, Associate Professor of Law, Societies, and Justice, and of International Studies, University of Washington, Sociology Department |
| Thursday, April 5 |
Ian Kerr, Canada Research Chair in Ethics, Law & Technology, Faculty of Law, University of Ottawa [CANCELLED] ABSTRACT: Recent medical advances allow us to transcend biological limitations through the implantation of microchips, digital body parts and artificial organs. However, surprisingly little thought has been given to the ethical and legal aspects of their design and use. In this seminar, Ian Kerr, Canada Research Chair in Ethics, Law and Technology, examines current ethical and regulatory approaches that govern medical devices and argues that the existing paradigm of mass-market consumer goods is not particularly well suited for the health sector. His primary concern is that individuals are increasingly called upon to sign complex contractual documents that diminish privacy and autonomy not only as users of mass market consumer goods but, now, as medical patients. Drawing on lessons learned in the field of privacy and information technology law, he suggests that special considerations are required in the healthcare context to ensure that patient autonomy and privacy are adequately protected in an era where our bodies are becoming inextricably tethered by devices and software owned by health care providers in partnership with industry. |
|
|
|